Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2390-2396

  Ezzat, Hatoon M ^a   Cheung, Matthew C ^b   Hicks, Lisa K ^c   Boro, Jordana ^d   Montaner, Julio S G ^a   Lima, Viviane Dias ^a   Harris, Marianne ^a   Leitch, Heather A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP3A4; HIV; Hodgkin lymphoma; Protease inhibitors; Treatment toxicity; Vinblastine

Indexed keywords

ABACAVIR; ATAZANAVIR; ATOVAQUONE; BLEOMYCIN; CHLORMETHINE; COTRIMOXAZOLE; DACARBAZINE; DAPSONE; DOXORUBICIN; EFAVIRENZ; EMTRICITABINE; FLUCONAZOLE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NYSTATIN; PREDNISONE; PROCARBAZINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VALACICLOVIR; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; DISEASE SEVERITY; ENCEPHALITIS; FEBRILE NEUTROPENIA; FEMALE; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TOXICITY; MALE; NEUROTOXICITY; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FEMALE; HEMATOLOGIC DISEASES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HODGKIN DISEASE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOPINAVIR; LUNG DISEASES; MALE; MECHLORETHAMINE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PREDNISONE; PROCARBAZINE; PROGNOSIS; RETROSPECTIVE STUDIES; RITONAVIR; VINBLASTINE; VINCRISTINE;

EID: 84868344890     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.697560     Document Type: Article

References (38)

1. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009;113:5737-5742.
2. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006;108: 3786-3791. (Pubitemid 44864560)
3. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010;103:416-422.
4. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011;117:1089-1096.
5. Ezzat H, Filipenko D, Vickars L, et al. Improved survival in HIVassociated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin Trials 2007;8:132-144. (Pubitemid 47121758)
6. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15: 1483-1491. (Pubitemid 32744595)
7. Navarro JT, Ribera JM, Oriol A, et al. Infl uence of highly active antiretroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001;112:909-915. (Pubitemid 32322915)
8. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multiinstitutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000;24:444-450.
9. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004;125:455-462. (Pubitemid 38916190)
10. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007;92:191-198.
11. Chemotherapy protocols. Lymphoma & myeloma [Internet]. Available from: http://www.bccancer.bc.ca/HPI/Chemotherapy Protocols
12. Yao D, Ding S, Burchell B, et al. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000;294: 387-395. (Pubitemid 30434712)
13. Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121-5126. (Pubitemid 23333376)
14. Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977;37:2597-2602.
15. Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:E22-E25.
16. Stein H. Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp. 321-334.
17. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-614. (Pubitemid 46621893)
18. NCI Common Toxicity Criteria [Internet]. Available from: http://evs.nci.hih.gov/ftpi/CTCAE/CTCAE-4.03-2010-06-14
19. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin' s disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
20. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10:412-426. (Pubitemid 40993569)
21. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001;19:3848-3851. (Pubitemid 32880063)
22. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344.
23. Chow KU, Mitrou PS, Geduldig K, et al. Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001;41:105-116. (Pubitemid 32294194)
24. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-3412.
25. Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730-2734.
26. Navarro JT, Ribera JM, Oriol A, et al. Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;32: 347-348. (Pubitemid 36331710)
27. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;37:1556-1564. (Pubitemid 37494686)
28. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
29. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIVassociated multicentric Castleman's disease. Eur J Haematol 2006; 76:269-271.
30. Makinson A, Martelli N, Peyriere H, et al. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol 2007;78:358-360. (Pubitemid 46365089)
31. Martin P, Leonard JP, Coleman M, et al. Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma 2009;9:247-249.
32. Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. AIDS 2010;24:2408-2412.
33. Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57:1147-1152. (Pubitemid 29171690)
34. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:7614-7620. (Pubitemid 46291825)
35. O' Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003;14:91-96. (Pubitemid 36150265)
36. Simpson AB, Paul J, Graham J, et al. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998;78:1061-1066. (Pubitemid 28463983)
37. Blum RH, Carter SK, Agre K. A clinical review of bleomycin-a new antineoplastic agent. Cancer 1973;31:903-914.
38. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15: 1483-1491. (Pubitemid 32744595)